RSPO2基因重排:肝肿瘤中β-连环蛋白激活的强大驱动因素
研究在大队列肝细胞腺瘤(n=185)和肝细胞癌(n=468)中寻找可功能性替代CTNNB1突变的遗传改变,发现8q23.1染色体46.4kb微缺失导致的RSPO2基因重排是β-连环蛋白激活型HCA的新驱动因素,可致癌性激活WNT信号通路,并可能在没有额外TERT启动子突变的情况下驱动恶性转化。
要点
- RSPO2基因重排是β-连环蛋白激活型肝细胞腺瘤的新形态分子驱动因素。
- RSPO2融合阳性HCA显示RSPO2蛋白上调、β-连环蛋白核积聚及WNT靶基因转录激活。
- RSPO2重排亦见于慢性肝病背景下的β-连环蛋白激活型肝细胞癌。
核心结论
- RSPO2基因重排导致HCA和HCC中WNT信号通路的致癌性激活,是β-连环蛋白激活型HCA发生的替代机制,并可能在没有额外TERT启动子突变的情况下驱动恶性转化。
研究设计与样本
- 研究纳入大队列肝细胞腺瘤(n=185)和肝细胞癌(n=468),通过免疫组化分类,对β-连环蛋白激活型HCA及至少中度核CTNNB1积聚的HCC测定CTNNB1突变状态。
- 采用超深度测序表征CTNNB1野生型且β-连环蛋白激活的HCA和HCC,并对HCA亚型进行表达谱分析。
主要发现
- 检测到由8q23.1染色体46.4 kb微缺失导致的RSPO2基因重排,作为β-连环蛋白激活型HCA的新形态分子驱动因素。
- RSPO2融合阳性HCA显示RSPO2蛋白上调、β-连环蛋白核积聚及β-连环蛋白靶基因转录激活,提示WNT信号通路激活。
- 一例RSPO2重排的β-连环蛋白激活型HCA中,结构性和细胞学异型性及间质浸润提示恶性转化。
- 在慢性肝病背景下发生的三例β-连环蛋白激活型HCC中也观察到RSPO2基因重排。
- 已知驱动CTNNB1突变型HCA恶性转化的人端粒酶逆转录酶启动子突变,对于RSPO2重排的HCA和HCC似乎并非必需。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed at the identification of genetic alterations that may functionally substitute for CTNNB1 mutation in ß-catenin-activated hepatocellular adenomas (HCAs) and hepatocellular carcinoma (HCC). DESIGN: Large cohorts of HCA (n=185) and HCC (n=468) were classified using immunohistochemistry. The mutational status of the CTNNB1 gene was determined in ß-catenin-activated HCA (b-HCA) and HCC with at least moderate nuclear CTNNB1 accumulation. Ultra-deep sequencing was used to characterise CTNNB1wild-type and ß-catenin-activated HCA and HCC. Expression profiling of HCA subtypes was performed. RESULTS: A roof plate-specific spondin 2 (RSPO2) gene rearrangement resulting from a 46.4 kb microdeletion on chromosome 8q23.1 was detected as a new morphomolecular driver of β-catenin-activated HCA. RSPO2 fusion positive HCA displayed upregulation of RSPO2 protein, nuclear accumulation of β-catenin and transcriptional activation of β-catenin-target genes indicating activation of Wingless-Type MMTV Integration Site Family (WNT) signalling. Architectural and cytological atypia as well as interstitial invasion indicated malignant transformation in one of the RSPO2 rearranged b-HCAs. The RSPO2 gene rearrangement was also observed in three β-catenin-activated HCCs developing in context of chronic liver disease. Mutations of the human telomerase reverse transcriptase promoter-known to drive malignant transformation of CTNNB1-mutated HCA-seem to be dispensable for RSPO2 rearranged HCA and HCC. CONCLUSION: The RSPO2 gene rearrangement leads to oncogenic activation of the WNT signalling pathway in HCA and HCC, represents an alternative mechanism for the development of b-HCA and may drive malignant transformation without additional TERT promoter mutation.
引用
- Longerich T, Endris V, Neumann O, et al. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut. 2019. PMID: 30901310. doi:10.1136/gutjnl-2018-317632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。